NASDAQ:ARAVAravive Stock Price, Forecast & News

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARAV shares have increased by 19.8% and is now trading at $5.98.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aravive.

Aravive is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aravive.

Aravive Inc (NASDAQ:ARAV) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.14.
View Aravive's earnings history.

5 equities research analysts have issued 1-year price objectives for Aravive's shares. Their forecasts range from $26.00 to $31.00. On average, they expect Aravive's stock price to reach $28.75 in the next twelve months. This suggests a possible upside of 380.8% from the stock's current price.
View analysts' price targets for Aravive.

Media coverage about ARAV stock has trended positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aravive earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Aravive.

Aravive saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,020,000 shares, an increase of 15.5% from the July 15th total of 883,400 shares. Based on an average daily trading volume, of 180,700 shares, the days-to-cover ratio is presently 5.6 days. Currently, 11.4% of the shares of the company are short sold.
View Aravive's Current Options Chain.

Some companies that are related to Aravive include Amryt Pharma (AMYT), Kamada (KMDA), Xenon Pharmaceuticals (XENE), Ovid Therapeutics (OVID), Merus (MRUS), Atreca (BCEL), Albireo Pharma (ALBO), ANI Pharmaceuticals (ANIP), AMAG Pharmaceuticals (AMAG), Axovant Sciences (AXON), Progenics Pharmaceuticals (PGNX), CytomX Therapeutics (CTMX), BIOFRONTERA AG/ADR (BFRA), Passage Bio (IMRA) and Seres Therapeutics (MCRB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.17%), Alps Advisors Inc. (0.14%) and New York State Common Retirement Fund (0.07%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju.
View institutional ownership trends for Aravive.

ARAV stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., New York State Common Retirement Fund, and Wedbush Securities Inc..
View insider buying and selling activity for Aravive.

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $5.98.

Aravive has a market capitalization of $95.80 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]